National Health (Price and Special Patient Contribution) Amendment Determination 2022 (No. 5) (Cth)
PB 50 of 2022
National Health (Price and Special Patient Contribution) Amendment Determination 2022 (No. 5)
I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make the following Determination.
Dated 25 May 2022
NIKOLAI TSYGANOV
Acting Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
Contents
1 Name........................................................................................................................................ 1
2 Commencement........................................................................................................................ 1
3 Authority.................................................................................................................................. 1
4 Schedules................................................................................................................................. 1
Schedule 1—Amendments 2
National Health (Price and Special Patient Contribution) Determination 2021 (PB 35 of 2021) 2
1 Name
This instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2022 (No. 5).
This instrument may also be cited as PB 50 of 2022.
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
| Commencement information | ||
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 June 2022 | |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under section 85B of the National Health Act 1953.
4 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Price and Special Patient Contribution) Determination 2021 (PB 35 of 2021)
Schedule 1, omit entry for Enalapril with Hydrochlorothiazide
Schedule 1, omit entry for Ipratropium
Schedule 1, after entry for Medroxyprogesterone
Insert
| Mefenamic acid | Capsule 250 mg | Oral | Ponstan | 50 | 5.79 | 7.72 |
Schedule 1, entry for Rosuvastatin
Omit
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | Crestor | 30 | 1.70 | 4.56 |
| Tablet 10 mg (as calcium) | Oral | Crestor | 30 | 3.16 | 5.98 | |
| Tablet 20 mg (as calcium) | Oral | Crestor | 30 | 3.55 | 6.34 | |
| Tablet 40 mg (as calcium) | Oral | Crestor | 30 | 5.06 | 8.65 |
Substitute
| Rosuvastatin | Tablet 5 mg (as calcium) | Oral | Crestor | 30 | 1.70 | 5.16 |
| Tablet 10 mg (as calcium) | Oral | Crestor | 30 | 3.16 | 6.53 | |
| Tablet 20 mg (as calcium) | Oral | Crestor | 30 | 3.55 | 6.89 | |
| Tablet 40 mg (as calcium) | Oral | Crestor | 30 | 5.06 | 9.16 |
Schedule 1, entry for Spironolactone
Omit
| Spironolactone | Tablet 25 mg | Oral | Aldactone | 100 | 3.50 | 10.61 |
| Tablet 100 mg | Oral | Aldactone | 100 | 13.77 | 20.75 |
Substitute
| Spironolactone | Tablet 25 mg | Oral | Aldactone | 100 | 3.50 | 10.61 |
| Spiractin 25 | 100 | 3.50 | 7.82 | |||
| Tablet 100 mg | Oral | Aldactone | 100 | 13.77 | 20.75 | |
| Spiractin 100 | 100 | 13.77 | 17.96 |
Schedule 1, entry for Trimethoprim
Omit
| Trimethoprim | Tablet 300 mg | Oral | Triprim | 7 | 1.58 | 5.28 |
Substitute
| Trimethoprim | Tablet 300 mg | Oral | Alprim | 7 | 1.58 | 4.15 |
| Tablet 300 mg | Oral | Triprim | 7 | 1.58 | 5.28 |
Schedule 1, after entry for Valproic Acid
Insert
| Venlafaxine | Capsule (modified release) 75 mg (as hydrochloride) | Oral | Efexor-XR | 28 | 3.35 | 5.35 |
| Capsule (modified release) 150 mg (as hydrochloride) | Oral | Efexor-XR | 28 | 4.08 | 6.04 |
0
0
0